medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2002, Número 1

<< Anterior Siguiente >>

Ann Hepatol 2002; 1 (1)


Treatment of nonalcoholic fatty liver disease

Angulo P

Idioma: Español
Referencias bibliográficas: 65
Paginas: 12-19
Archivo PDF: 102.61 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ludwig J, Viggiano RT, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experience with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 342-348.

  2. Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis 1986; 8: 283-286.

  3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002 (in press).

  4. Lee RG. Nonalcoholic steatohepatitis. A study of 49 patients. Hum Pathol 1989; 20: 594-599.

  5. Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: A follow up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.

  6. Bacon BR, Farahvash MJ, Janney CG, et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107; 1103-1109.

  7. Teli M, Oliver FW, Burt AD, et al. The natural history of nonalcoholic fatty liver: A follow up study. Hepatology 1995; 22: 1714-1717.

  8. Matteoni CA, Younossi ZM, Gramlich TL, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.

  9. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-1123.

  10. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-1362.

  11. Diehl AM, Goodman Z, Ishak KG. Alcohol-like liver disease in nonalcoholic. A clinical and histological comparison with alcohol-induced liver injury. Gastroenterology 1989; 95: 1056-1060.

  12. Eriksson S, Eriksson KF, Bondesson L. Nonalcoholic steatohepatitis in obesity: a reversible condition. A Med Scand 1986; 220: 83-88.

  13. Rozental P, Biava C, Spencer H, et al. Liver morphology and function tests in obesity and during total starvation. A J DigDis 1967; 12: 198-208.

  14. Drenick EJ, Simmons F, Murphy J. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets, and small bowel bypass. N Engl J Med 1970; 282: 829-834.

  15. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99: 1408-1413.

  16. Andersen T, Gluud C, Franzmann MB, et al. Hepatic effects of dietary weight loss in morbidly obese patients. Hepatology 1991; 12: 224-229.

  17. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. Hepatology 1997; 27: 103-107.

  18. Vajro P, Fontanella A, Perna C, et al. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr 1994; 125: 239-241.

  19. Franzese A, Vajro P, Argenziano A, et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997; 42: 1428-1432.

  20. Rashid M, Roberts E. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol and Nutr 2000; 30: 48-53.

  21. Kanders BS, Blackburn GL. Very-low-calorie diets for the treatment of obesity. In: Blackburn GL, Kanders BS (eds) Obesity: Pathophysiology, Psychology and Treatment. New York: Chapman and Hall. 1994: 197-215

  22. Kolanowski J. A risk-benefit assessment of anti-obesity drugs. Drug Safety 1999; 20: 119-131.

  23. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609-616.

  24. Lin HZ, Yang SQ, Chuckaree C, et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000; 6: 998-1003.

  25. DeWind LT, Payne JH. Intestinal bypass surgery for morbid obesity. Long term results. JAMA 1976; 236: 2298-2301.

  26. Campbell JM, Hung TK, Karam JH, et al. Jejunoileal bypass as a treatment of morbid obesity. Arch Inter Med 1977: 137: 602-610.

  27. Ackerman NB. Protein supplementation in the management of degenerating liver function after jejunoileal bypass. Surg Gynecol and Obst 1979; 149: 8-14.

  28. Drenick EJ, Fisler J, Johnson D. Hepatic steatosis after intestinal bypass. Prevention and reversal by metronidazol, irrespective of protein-calorie malnutrition. Gastroenterology 1982; 82: 535-548.

  29. Buchman AL, Dubin M, Jenden D, et al. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition in rats. Gastroenterology 1992; 102: 1363-1370.

  30. Buchman AL, Dubin MD, Moukarzel AA, et al. Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Hepatology 1995; 22: 1390-1403.

  31. Pappo I, Becovier H, Berry EM, et al. Polymixin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in rat. J Surg Res 1991; 51: 106-112.

  32. Freud HR, Muggia-Sullan M, LaFrance R, et al. A possible beneficial effect of metronidazol in reducing TPN-associated liver function derangements. J Surg Res 1985; 38: 356-363.

  33. Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of nonalcohol-induced steatohepatitis: A pilot study. Hepatology 1996; 23: 1464-1467.

  34. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999; 31: 384.

  35. Guma G, Viola L, Thome M, et al. Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis: Results of a prospective clinical controlled trial [Abstract]. Hepatology 1997; 26: 387A.

  36. Ceriani R, Bunati S, Morini L, et al. Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis [Abstract]. Hepatology 1998; 28: 386A.

  37. Holoman J, Glasa J, Kasar J, et al. Serum markers of liver fibrosis in patients with non-alcoholic steatohepatitis (NASH). Correlation to liver morphology and effect of therapy. J Hepatology 2000; 32: 210.

  38. Barak AJ, Beckenhauer HC, Junnila M, et al. Dietary betaine promotes generation of hepatitic S-adenosylmethionine and protects the liver from ethanol-induced fatty infiltration. Alcohol Clin Exp Res 1993; 17: 552-555.

  39. Abdelmalek M, Angulo P, Jorgensen RA, et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001; 96: 2711-2717.

  40. Gulbahar O, Karasu ZA, Ersoz G, et al. Treatment of non-alcoholic steatohepatitis with N-acetylcysteine [Abstract]. Gastroenterology 2000; 118: A1444.

  41. Hasegawa T, Yoneda M, Nakamura K, et al. Long-and short-term d-alpha-tocopherol supplementation inhibits liver collagen alpha-1(I) gene expression [Abstract]. Hepatology 1997; 26: 250A.

  42. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study. J Pediatr 2000; 136: 734-738.

  43. Hasegawa T, Yoneda M, Nakamura K, et al. Plasma trnasforming growth factor-b1 level and efficacy of a-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol and Ther 2001; 15: 1667-1672.

  44. Angulo P, Lindor KD. Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue. Gastroenterology 2001; 120: 1281-1285.

  45. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999; 16: 179-192.

  46. Caldwell SH, Hespenheiden EE, Redick JA, et al. A pilot study of thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 519-525.

  47. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338: 908-909.

  48. Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-894.

  49. Letterson P, Fromenty B, Terris B, et al. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1996; 24: 200-208.

  50. Jaeschke H, Wang Y, Essani NA. Reactive oxygen species activate the transcription factor NF-kB in the liver by induction of lipid peroxidation [Abstract]. Hepatology 1996; 24: 238A.

  51. Acosta D, Wenzel DG. Injury produce by free fatty acids to lysosomes and mitochondria in cultures heart muscle and endothelial cells. Atherosclerosis 1974; 20: 417-426.

  52. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996; 111: 1645-1653.

  53. Leclercq IA, Farrell GC, Field J, et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis. J Clin Investi 2000; 105: 1067-1075.

  54. Weltman MD, Farrel GC, Hall P, et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27: 128-133.

  55. Schuppan D, Jia JD, Brinkhaus B, et al. Herbal products for liver diseases. A therapeutic challenge for the new millennium. Hepatology 1999; 30: 1099-1104.

  56. Yang SQ, Lin HZ, Lane MD, et al. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. PNAS 1997; 94: 2557-2562.

  57. Chavin KD, Yang SQ, Lin HZ, et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 1999; 274: 5692-5700.

  58. Cortez-Pinto H, Chatham J, Chacko VP, et al. Alterations in liver ATP homeostasis in human nonalcoholic steatoheaptitis. A pilot study. JAMA 1999; 282: 1659-1664.

  59. George DK, Goldwurm S, MacDonald GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-318.

  60. Boncovsky HL, Jawaid Q, Tortorelli K, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 421-429.

  61. Younossi ZM, Gramlich T, Bacon BR, et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999; 30: 847-850.

  62. Desai TK. Phlebotomy reduces transaminase levels in patients with non-alcoholic steatohepatitis [Abstract]. Gastroenterology 2000; 118: A975.

  63. Nitecki J, Jackson FW, Allen ML, et al. Effect of phlebotomy on non-alcoholic steatohepatitis (NASH) [Abstract]. Gastroenterology 2000; 118: A1474.

  64. Charlton M, Kasparova P, Weston S, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001; 7: 608-614.

  65. Contos MJ, Cales W, Sterling RK, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001; 7: 363-373.




2020     |     www.medigraphic.com